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ABSTRACT 27 
 28 
Objective 29 
 30 
Combined surgery and platinum-based chemotherapy is the internationally agreed standard 31 
therapy for advanced ovarian cancer (AOC). However international cancer registry datasets 32 
demonstrate a significant proportion of patients do not receive both or either therapies. Our 33 
objective was to evaluate the effect of total patient cohort data (‘Denominator’) on median 34 
overall survival (OS) and determine how frequently this was reported in literature. 35 
 36 
Methods 37 
 38 
We retrospectively reviewed OS outcomes for 593 patients diagnosed with AOC for 77 39 
months at a regional cancer centre. Patients were stratified into five progressively 40 
overlapping categories based on treatment received - Primary debulking surgery (PDS), PDS 41 
or Interval debulking (IDS), all surgery and those considered for IDS, patients receiving any 42 
treatment and total patient cohort. A systematic search of literature was performed. 43 
 44 
Results 45 
 46 
Median OS progressively decreased from 54.5 months in patients receiving PDS, 38.7 47 
months in the PDS +IDS group, 35.4 months in the PDS/IDS + patients considered for IDS, 48 
33.3 months in patients receiving any treatment and 30.2 months in the total patient cohort. 49 
OS in the surgically treated group was statistically significantly different from the OS in the 50 
total patient cohort (Denominator)(p=0.000353). Denominator descriptors were identified in 51 
11% of studies.  52 
 53 
Conclusions 54 
 55 
Denominator data is critical to understanding selection and OS in AOC. Published outcomes 56 
of selected cohorts should routinely incorporate outcomes for all women managed within the 57 
reporting Centre.  This is essential for benchmarking and quality assurance in gynaecological 58 
cancer and should be an integral part of any publication on outcomes from AOC. 59 
 60 
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INTRODUCTION  63 
 64 
Disease burden with cytoreductive outcomes following debulking surgery and platinum 65 
sensitivity are two of the strongest predictors of survival in advanced ovarian cancer 66 
(AOC)(1-3). As such, the importance of surgery is reflected in published international 67 
guidelines(4, 5).  However, both the United States SEER data and the United Kingdom 68 
Cancer registry datasets demonstrate that up to 44% of patients with AOC do not receive 69 
optimum therapy(6, 7). Explanations for such deviations in care include: elderly patients; 70 
emergency presentations; unclear histology; significant co-morbidities; as well as patient 71 
choice(7-9). Investigating the underlying factors for this under-treated group has been 72 
difficult with limited data recorded in national databases in these patients compared to their 73 
counterparts who receive treatment(9).  74 
 75 
In contrast, there are numerous publications, mainly single centre based, on the success 76 
associated with primary cytoreductive surgery where attempted(10-16). In this latter group, 77 
survival data is often presented without reference to the population from which they are 78 
derived. This makes it impossible to ascertain the selection processes which resulted in the 79 
reported patient cohort. Patient selection in AOC between centres can vary by: i) by the 80 
proportion of patients selected at each centre to receive any treatment; ii) those managed by 81 
primary surgery vs neoadjuvant chemotherapy and; iii) finally by the proportion who 82 
following neoadjuvant chemotherapy have debulking surgery. All of these variables may 83 
render the population reported showing an excellent outcome (e.g. by selecting only those 84 
with a high chance of complete cytoreduction) or a poorer outcome (by a policy that all 85 
patients are exposed to primary surgery).  Failure to report the proportion of patients 86 
receiving each treatment modality therefore risks bias, with centres that routinely operate on 87 
patients with more disseminated disease potentially reporting inferior survival data in their 88 
surgical arm compared to centres that would routinely manage similar patients with the same 89 
tumour load with chemotherapy or palliation. The more aggressive centres may however 90 
have superior overall survival (OS) data because they are operating on a greater proportion of 91 
patients. We define the denominator as the total number of advanced ovarian cancer cases 92 
presenting referred to a specific cancer centre or within the catchment area of a cancer centre 93 
and describe the survival shift as the ‘denominator effect’.  94 
 95 
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In this study, we evaluate the effect of the denominator on the survival of the total AOC cases 96 
in a systematic literature search of published literature and data from our cancer centre. 97 
 98 
 99 
Methods 100 
 101 
We undertook a retrospective review of all patients diagnosed with stage 3 or 4 AOC 102 
between 16
th
 August 2007 and 3
rd
 February 2014. All patients were managed by subspecialty 103 
trained gynaecological oncologists at the Pan-Birmingham Gynaecological Cancer Centre 104 
(PBGCC), Birmingham, United Kingdom, which serves a population of 2.2 million people. 105 
All patients were discussed at the Centre Multi-disciplinary team meeting (MDT) and 106 
prospectively recorded in an electronic database. The UK system of healthcare necessitates 107 
the management of every ovarian cancer patient within this population to be discussed at the 108 
PBGCC MDT. Approval for this study was obtained from the hospital clinical effectiveness 109 
department.  110 
 111 
All consecutive patients diagnosed with stage 3 or 4 epithelial ovarian, tubal or peritoneal 112 
cancer were identified from the database, along with those lacking a histological confirmation 113 
but diagnosed based on imaging and biochemical findings and agreed as AOC by the MDT. 114 
All women with suspected AOC underwent a clinical examination, transvaginal ultrasound 115 
scan, serum CA125 assay and CT scan of the thorax, abdomen and pelvis, with imaging 116 
reviewed by specialist gynaecological cancer radiologists.   Following discussion at the MDT 117 
meeting, women either underwent: primary debulking surgery (PDS), 3-4 cycles carboplatin 118 
AUC 6 +/- paclitaxel 175mg/m
2
 based neoadjuvant chemotherapy (NACT) with an intention 119 
to consider interval debulking surgery (IDS), or palliation of symptoms alone (no 120 
cytoreductive surgery or chemotherapy). Our standard approach to advanced ovarian cancer 121 
is PDS followed by 6 cycles of platinum based adjuvant chemotherapy. However, patients 122 
with stage 4 disease, poor performance status (ECOG/WHO 3-4), obvious porta hepatis 123 
involvement on scan, small bowel mesenteric or extensive serosal involvement on diagnostic 124 
laparoscopy, or with large amount of ascites/pleural effusions with low albumin level are 125 
offered 3 cycles of platinum based NACT to enhance their feasibility to radical surgery with 126 
3 - 5 further cycles of adjuvant chemotherapy. This is in-keeping with international 127 
guidelines of practice(17, 18). Contraindications for IDS consist of progressive disease on 128 
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NACT, worsening performance status, severe cardiovascular disease and patient choice. All 129 
patients with a response on CT/CA125 or clinical indicators are considered for IDS.  The 130 
PBGCC was an early adopter of advanced upper abdominal surgical procedures in the UK 131 
with complete (R0) and optimal (<1cm) (R1) cytoreduction rates of 62.2% and 14.3% 132 
respectively in AOC. Detailed surgical outcomes have been previously published(19). 133 
Gynaecological cancer care in the UK National Health Service (NHS) is delivered at 134 
designated regional cancer centres that are responsible for the care of all women with 135 
gynaecological malignancies within a specific catchment population. For illustration, the 136 
PBGCC manages all patients with gynaecological cancer within a 2.2 million catchment 137 
population. Although patient-initiated referrals to other providers are achievable, the NHS 138 
system focuses referrals to named providers within a gynaecological cancer centre. Referrals 139 
for private care are relatively uncommon and still necessitate discussion at, and notification 140 
to, the MDT of the regional cancer centre. Referrals to other cancer centres are uncommon 141 
and usually occur when a specific second opinion is required often after initial treatment has 142 
been implemented.  As such, within the UK NHS all women with ovarian cancer within a 143 
designated region are likely to be registered with a specified cancer centre.  144 
The following data were analysed: age; performance status (PS); age-adjusted Charleston co-145 
morbidity index (ACCI); Deprivation score (LSOA)(20); stage; organ of origin; histology; 146 
treatment received; cytoreduction rate; surgical complexity score (SCS)(12); and survival 147 
data. We classified our total patient cohort by mode of treatment received into five 148 
progressively overlapping groups: group A comprised patients who underwent PDS; group B 149 
comprised patients in group A and also included all patients who underwent IDS; group C 150 
comprised patients in group B and also included patients who underwent assessment for IDS 151 
but who did not eventually undergo surgery; group D included patients in group C and also 152 
included all patients treated with chemotherapy alone; and group E included all patients in 153 
group D and also included all patients who did not receive any treatment. Group E therefore 154 
represents the total patient cohort ‘denominator’ and consists of all patients managed by our 155 
cancer centre. These groups are illustrated in Figure 1. We investigated whether survival and 156 
other variables differed between these five groups.  157 
We performed a systematic search of EMBASE databases between 1996 to Week 03 2017 158 
using a combination of text words “ovarian ca*” and Medical Subject Headings “surgery” or 159 
“ovary cancer” to generate a subset of citations relevant to the research question. Search was 160 
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limited to studies involving human subjects, published in the English language, between 161 
1.1.16 and 31.12.16. Duplicate papers were removed, as were commentaries, narrative 162 
reviews and letters. Additional papers were identified from reference lists and previously 163 
identified studies. Inclusion criteria consisted of:  prospective or retrospective, single centre, 164 
cohort studies of surgically treated stage 3-4 AOC that presented OS data. Exclusion criteria 165 
consisted of: multicentre studies, randomised controlled trials of chemotherapy or papers 166 
where OS data could not be extracted.  Papers were selected from their abstracts by one 167 
author (AP) with a second review by another (SS) where inclusion or exclusion was unclear. 168 
The EMBASE database was last interrogated on 18/1/17. 169 
  170 
Statistical Analysis 171 
 172 
Categorical variables were compared with the chi-squared test and parametric and non-173 
parametric continuous variables were compared with the ANOVA or Kruskal-Wallis test 174 
respectively. All tests were two-sided and a p-value of less than 0.05 was regarded as being 175 
statistically significant. All tests were two-sided and a p-value of less than 0.05 was regarded 176 
as statistically significant. The Kaplan-Meier method was used to estimate survival with 177 
survival compared using the Log rank method with IBM SPSS version 20. 178 
 179 
Results 180 
 181 
 182 
Between 16
th
 August 2007 and 3
rd
 February 2014, 593 women diagnosed with advanced 183 
ovarian cancer (AOC) were identified from the database. Of these, 441 (74.4%) patients 184 
received either PDS (n=146) or IDS after NACT (n=295), and 152 (25.6%) patients received 185 
no cytoreductive surgery. The clinico-pathological data comparing those that did and did not 186 
undergo surgery is summarised in Table 1.  Patients who did not undergo surgery were 187 
significantly older (p<0.00001), had a worse performance status (p<0.00001), a higher ACCI 188 
(p<0.00001), lived in more deprived regions (p<0.00001), presented with more advanced 189 
disease (p=0.0001) and were more likely not to have a histological diagnosis of their 190 
malignancy (p<0.00001). 191 
 192 
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Figure 1 summarises study population by treatment received. Of the 152 patients that did not 193 
receive any cytoreductive surgery, 25 were considered for palliation of symptoms only due to 194 
poor performance status that precluded any cancer treatment either with chemotherapy or 195 
cytoreductive surgery.  NACT was recommended for 123 patients but only commenced in 196 
104 patients due to 14 patients dying prior to NACT and five patients declining NACT.  197 
Thirteen patients did not complete all their NACT cycles due to either death or intolerance. 198 
The remaining 91 patients completed all their planned NACT cycles and were subsequently 199 
considered for IDS (but did not receive it).  Failure to receive IDS was most commonly due 200 
to: poor performance status or co-morbidities (n= 30); progressive disease following NACT 201 
(n=24); no response to NACT (n=21); patient refusal of IDS (n=7); issues pertaining to 202 
disease distribution (n=7); dying prior to IDS (n=1); or, unknown (n=1). 203 
 204 
Patients who did not receive cytoreductive surgery were considered in three groups: (1) all 205 
those who did not receive cytoreductive surgery (n=152); (2) those who were fit enough to 206 
undergo NACT (but did not necessarily receive it) (n=123); and (3) those who completed 207 
NACT and were considered for IDS (but did not undergo it) (n=91). The median OS of 208 
patients in group 1 was 11.3 months (95% CI 7.8-15.0).  The corresponding value for patients 209 
in group 2 and 3 were 14.0 (95% CI 10.2-17.7) and 19.1 (95% CI 15.8-22.5) months 210 
respectively. 211 
 212 
Five of the 123 patients that were fit enough to undergo NACT declined chemotherapy.  213 
Seven of the 91 patients that completed NACT and were considered for IDS declined 214 
surgery.  The median OS for the former group of patients was 6.1 months (95% CI 0.9-11.4) 215 
whilst those patients in the latter group had not reached median OS by 33 months of follow 216 
up.  217 
 218 
To illustrate the ‘denominator effect’, we analysed the median OS for the five groups of 219 
patients as described in Methods. OS progressively decreased from Group A patients (n=140) 220 
with the median OS 54.5 (35.7 – 73.3) months, Group B (n=441) with  median OS 38.7 (34.9 221 
– 42.4) months,   Group C (n= 532) with median OS 35.4 (31.9 – 38.8) months, Group D 222 
(n=564) with median OS 33.3 (29.8 – 36.8) months and Group E, the total patient cohort 223 
‘Denominator’ with AOC (n=593 with  median OS of 30.2 (26.7 – 32.6) months (Table 2) 224 
 225 
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Comparison of median OS between Group A (patients receiving PDS) and Group E (the total 226 
patient cohort) demonstrated a highly statistically significant difference, p= 0.000586. There 227 
was a statistically significant difference between OS in Groups B and Group E, p = 0.000353 228 
and between Groups C and E, p = 0.039180. (Table 2 and Figure 2).   229 
 230 
Eighteen studies met the specified inclusion criteria(21-38) for the systematic search. Only 231 
two (11%) papers explicitly defined their total patient cohort(21, 27). Two additional papers 232 
(11%) used terms which were ambiguous in relation to the total patient population(34, 35).  233 
No papers presented OS for the total patient cohort although one(21) did include non-234 
operated patients with their surgical study cohort. Two papers (11%) documented the number 235 
of patients who received any therapeutic treatment(21, 27) with two papers (11%) ambiguous 236 
in their descriptions(34, 35). Although twelve papers (67%) explicitly described all patients 237 
receiving surgery(21, 23-25, 27-30, 32, 34-36) only four papers (22.2%) published their OS 238 
of all surgically managed patients(24, 28-30). Table 3 presents this and any comment on 239 
survival data. 240 
 241 
Discussion 242 
 243 
In this study, we highlight the effect of the denominator on survival using our centre survival 244 
data and the sparse description of denominators in published literature in AOC. To our 245 
knowledge, this is the first study to explicitly define the denominator in AOC and describe its 246 
relevance. Our study, demonstrates a significant difference in OS based on the total patient 247 
cohort ‘denominator’. Presenting denominator data would improve the understanding of the 248 
process of patient selection within any given Centre, standardise selection between centres 249 
and facilitate reducing selection bias which is inevitable in retrospective studies.  Importantly 250 
it would also help in understanding the underlying factors that preclude patients from 251 
receiving therapy, thus potentially improving outcomes. OS for AOC internationally 252 
continues to be poor with a five year survival of 30%(39). Unless we focus our efforts on 253 
understanding the whole patient cohort of ovarian cancer, including those that do not receive 254 
any treatment, obtaining improvements in OS will remain challenging. 255 
 256 
In our series, 25.6% of patients with AOC did not receive cytoreductive surgery, 4.9% of 257 
whom were too ill to receive any treatment beyond that of palliation (Figure 1). Such findings 258 
are consistent with the UKs National Cancer Data Repository which has on record that 44% 259 
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of patients diagnosed with AOC in the UK do not receive cytoreductive surgery and 25% do 260 
not receive any treatment beyond palliation(7). Such a high prevalence of undertreated 261 
patients is not unique to the UK with comparable corresponding figures from the American 262 
National Cancer Database (no surgery in 21% and no chemotherapy in 8.7%) and 263 
Surveillance, Epidemiology and End Results (SEER) Database (no surgery in 34.2% and no 264 
chemotherapy in 16.5%)(8, 9). 265 
 266 
Whilst this manuscript demonstrated the impact on survival based on the category of patient 267 
investigated, it is reasonable to expect that this denominator effect would impact as well on 268 
morbidity of treatment and quality of life post treatment(40). An explicitly defined 269 
denominator is crucial to efforts to benchmark survival between centres worldwide. The 270 
European Society of Gynaecological Oncology should be applauded for incorporating total 271 
denominator data into their recent quality standards for ovarian cancer(41). Such data can be 272 
used for self-assessment, for institutional quality assurance programs, for governmental 273 
quality assessment and eventually to build a network of certified centres for ovarian cancer 274 
surgery that are transparent about the quality of care they deliver and the survival data that 275 
their approach achieves.   276 
 277 
Unfortunately, such robust reporting is scant in the literature and potentially artificially 278 
inflates survival outcomes.  Our data represents every single patient with AOC based on 279 
histology, cytology and/or radiology and tumour markers in a centre serving a population of 280 
2.2 million. Patients in other health care systems may be triaged in different ways. It is likely 281 
that there will be variation in overall operating rates in nationalised healthcare systems 282 
compared to systems with significant patient and provider selection. The total patient 283 
denominator, may aid identification of those centres with an unselected patient cohort 284 
compared to those treating a predominantly triaged population with good fitness for surgery. 285 
The lack of total denominator data makes a fallacy of a centre’s “cytoreduction rate” or 286 
“primary surgery rate”. 287 
  288 
The importance of the total patient denominator has been established in numerous nationwide 289 
cancer audits in the United Kingdom, such as the “National Bowel Cancer Audit Report”(42) 290 
and the “National Oesophago-Gastric Cancer Audit”(43). Such basic data has allowed trends 291 
in patients receiving treatment to be followed at a local, regional and national level. Both 292 
these registers collect data in not only those who receive surgery but also those that, either 293 
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due to patient or disease factors, do not. The importance of denominator data for ovarian 294 
cancer should be considered no different to these other high risk and aggressive cancers. 295 
 296 
Even with the use of a denominator as simplistic as the total patient cohort there are still areas 297 
of contention. Firstly, is the issue of AOC being defined as stage 3 or 4 disease.  It is possible 298 
that the true overall patient denominator may be underestimated in cases with inadequate 299 
retroperitoneal or extra-pelvic exploration performed. Equally, diagnosis based on radiology 300 
and tumour markers alone may increase the denominator with non-ovarian tumours 301 
mimicking that of epithelial ovarian tubal and primary peritoneal cancers. The result of this 302 
being that centres with suboptimal staging practice or who are less aggressive in obtaining 303 
histological diagnosis are potentially going to present a cohort with inferior OS relative to 304 
their peers.  A potential solution would be to expand the denominator to include all stage 305 
distributions of patients with ovarian cancer and to declare the proportion who did not receive 306 
a histological diagnosis. The development of an outcomes “dataset” is beyond the remit of 307 
this paper but standardised reporting of denominator, stage, histological diagnosis as well as 308 
patient and disease descriptors would, we believe, be a tool to accurately categorise centres 309 
and allow greater interpretation of centres outcomes. The development of a “core outcome” 310 
set for ovarian cancer, as recommended by the COMET initiative would be a welcome 311 
development in this space(44, 45). Comparisons could then be made with centres with similar 312 
data distributions and thus allow their research findings to be appropriately implemented 313 
either more cautiously in centres with wider but more heterogenous patient group or more 314 
rapidly in similar centres.  315 
 316 
As an important initial step, we suggest that to enable accurate interpretation of prospective 317 
or retrospective cohort surgical studies in AOC, the minimum denominator descriptors that 318 
should be provided should include the total number of patients as well as the total number of 319 
patients operated on. Indeed, the absence of such denominator data risks a disservice to 320 
studies that are innovative in their conclusions.  321 
  322 
In conclusion, the denominator of advanced cancer cases in each centre is critical to 323 
understanding selection and survival. This is essential for benchmarking and quality 324 
assurance in gynaecological cancer and should be an integral part of any publication on 325 
outcomes from AOC. 326 
 327 
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 328 
Tables/Figures 329 
 330 
Table 1: Clinicopathological data of the total patient cohort presented comparing patients 331 
who did not undergo surgery with those who underwent surgical management of AOC 332 
Figure 1: Flowchart demonstrating patient outcomes for the total patient cohort 333 
‘denominator’. 334 
Table 2: Impact on median OS by group of patients analysed demonstrating the 335 
‘Denominator effect’. 336 
Figure 2: Kaplan-Meier curve comparing OS by patient groups A-E. 337 
Table 3: Reporting of denominator data, surgical cohort data and survival data in included 338 
studies 339 
 340 
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Table 1: Clinicopathological data of the total patient cohort presented comparing patients 
who did not undergo surgery with those who underwent surgical management of AOC 
 Non-surgical cases 
n = 152 
Surgical cases 
n  = 441 
p 
Age 72.3 
(95% CI 61.3 - 83.3) 
63.27 
(95% CI 51.46 - 75.08) 
<0.00001 
PS (Median IQR) 2 (1-2) (54 cases) 1 (0-1) (307 cases) <0.00001 
ACCI 4 (3-5) (70cases) 2 (0-3) (441 cases) <0.00001 
LSOA Deprivation Score 3 (2-5) 5 (2-7) <0.00001 
Stage      
3 92 60.5% 347 78.7% 0.000011 
4 56 36.8% 94 21.3% 0.000146 
Unstaged advanced 4 2.6% 0 0.0% 0.00063 
Site of origin      
Ovary 124 81.6% 322 73.0% 0.034988 
Peritoneal 28 18.4% 78 17.7% >0.05 
Tubal 0 0.0% 41 9.3% 0.000098 
Histology      
Serous 107 70.4% 348 78.9% 0.032121 
Serous low grade 3 2.0% 23 5.2% >0.05 
Mucinous 2 1.3% 3 0.7% >0.05 
MMMT 3 2.0% 22 5.0% >0.05 
Mixed Epithelial 1 0.7% 15 3.4% >0.05 
Psammomatous 1 0.7% 0 0.0% >0.05 
Clear Cell 2 1.3% 16 3.6% >0.05 
unknown 31 20.4% 3 0.7% <0.00001 
Mullerian 2 1.3% 2 0.5% >0.05 
Undifferentiated/Anaplastic 0 0.0% 4 0.9% >0.05 
Endometroid 0 0.0% 5 1.1% >0.05 
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Table 2. Impact on median OS by group of patients analysed demonstrating the 
‘Denominator effect’.  
 
Treatment group Median OS (months) 
(95% CI) 
p 
A: Patients undergoing PDS 54.5 (35.7 – 73.3) 0.000586 
B: Group A and patients undergoing IDS 38.7 (34.9 – 42.4) 0.000353 
C: Group B and patients assessed for IDS 35.4 (31.9 – 38.8) 0.039180 
D: All AOC patients receiving any treatment 33.3 (29.8 – 36.8) 0.393738 
E: All advanced ovarian cancer patients 30.2 (26.7 – 32.6) Reference 
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 Table 3: Reporting of denominator data, surgical cohort data and survival data in included studies  
Study Journal Stage Total 
operated 
patients 
Study group 
and number of 
patients  on 
whom survival 
data is 
presented  
 OS in study group (Median OS 
+/-95% CI) months or 5-year 
survival 
Denominator 
Data (Total 
patient 
number)  
Total Cohort OS (Median +/- 
95% CI) months or 5-year 
survival 
Ataseven et al 
(1) 
Gynecol Oncol 4 315 PDS:286 16 (12–20) - 50 (3–57) 355 PDS + No surgery: 30 (NACT 
patients excluded) 
Bachmann  et 
al (2) 
J Cancer 3c -4 Not stated R0/R1: 108 18.8 (9.7 – 27.9) - 30.5 (24.7 – 
57.3) 
Not stated Not stated 
Bian et al (3) Arch Gynecol Obstet 3c -4 339 IDS: 114 
PDS:225 
IDS: 25 (21.7–28.3)  
PDS: 25 (22.1–27.9) 
Not stated Not stated 
Feng et al (4) Gynecologic Oncology 1 - 4 625 625 51.40% Not stated Not stated 
Gadducci et al 
(5) 
Int J Gynecol Cancer 3c-4 384 IDS: 64  
PDS: 322 
IDS: 41.8%  
PDS: 69.3% 
Not stated Not stated 
Gill et al (6) Gynecol Oncol 3c -4 Not stated IDS (?R2): 45  
PDS (R2): 45 
IDS 28.2  
PDS: 16.8 
Not stated Not stated 
Heitz et al (7) Gynecol Oncol 3b-4 663 PDS: 578 49 (42–55) 739 Not stated 
Luo et al (8) Medicine 3c-4 370 Overall: 341 
PDS: 283 
IDS: 58 
Overall 50.0 (44.5–55.5) 
PDS: 51.0  
IDS: 41.0 
Not stated Not stated 
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 Legend: PDS = Primary debuking surgery; IDS = Interval debulking surgery; R0= Complete cytoreduction; R1 = Optimal <1cm residual disease; R2= 
Suboptimal >1cm residual disease; HIPEC = Hyperthermic intraperitoneal chemotherapy 
Medina-Franco 
et al (9) 
Ann Surg Oncol 3c-4 105 Overall: 105 
PDS: 42  
IDS: 63 
Overall: 38 
PDS: 33.59  
IDS: 56.4 
Not stated Not stated 
Mueller et al 
(10) 
Gynecol Oncol 3-4 581 581  
IDS: 149  
PDS: 432 
Overall 63.2 (55.3–73.2)  
PDS 71.7(59.8-not reached)  
IDS (42.9 (37.1–56.3) 
Not stated Not stated 
Munoz-Casares 
et al(11) 
Eur J Surg Oncol 3c-4 Not stated IDS + HIPEC: 
124 
49% Not stated Not stated 
Oseledchyk et 
al(12) 
Int J Gynecol Cancer 3-4 278 R1/R2: 96 19.5 - 32.9 Not stated Not stated 
Pereira et 
al(13) 
Surgical Oncology 3-4 Not stated 116 If alive: 169.8 If dead: 34.9 
months 
Not stated Not stated 
Phillips  et al  3-4 441 All surgery: 441 
PDS: 140 
 
All surgery: 38.7 (34.9-42.4). 
PDS: 54.5 (35.7-73.3)  
593 30.2 (26.7-32.6) 
Plotti et al(14) Eur J Surg Oncol 3-4 337 PDS: 154 48-52% Unclear Not stated 
Skof et al(15) Radiol Oncol. 3c-4 160 PDS: 80 
IDS 80 
PDS: 31.6 
IDS 24.8  
Unclear Not stated 
Stewart et 
al(16) 
Can J Surg 3-4 334 IDS: 156 
PDS: 178 
IDS: 33.4 
PDS 69.5 
Not stated Not stated 
Sun et al(17) Transl Oncol 3c-4 Not stated PDS + HIPEC: 46 74.0 (8.5-139.5) Not stated Not stated 
Xu et al(18) J Ovarian Res 3c - 4 Not stated IDS: 160 32.1 (27.1–37.1) Not stated Not stated 
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Figure 1: Flowchart demonstrating patient outcomes for the total patient cohort “denominator”
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Figure 2: Kaplan-Meier curve comparing OS by patient groups A-E. 
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Highlights 
 
 Survival from AOC is influenced by the total patient cohort 'denominator' 
 Literature on outcomes after surgery contain denominator descriptors infrequently 
 Denominator data is essential for benchmarking in gynaeoncology 
 Denominator data should be described in surgical studies 
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